Table 2.
Comparison of clinical factors between patients with and without musculoskeletal pain after discontinuing IM.
| Musculoskeletal pain after discontinuing IM |
|||
|---|---|---|---|
| Yes (n=7) | No (n=17) | p value | |
| Sex | male 3 female 4 | male 13 female 4 | 0.167* |
| Age (years) median (range) | 54 (44–84) | 63 (37–81) | 0.181** |
| Sokal category | low 4 intermediate 3 | low 16 intermediate 1 | 0.059* |
| Prior IFNα | yes 0 no 7 | yes 7 no 10 | 0.065* |
| Body height (cm) median (range) | 157.4 (154.3–168.5) | 166.3 (145.0–180.0) | 0.253** |
| Body weight (kg) median (range) | 49.9 (45.6–63.4) | 59.0 (47.0–82.6) | 0.013** |
| Body mass index (kg/m2) median (range) | 20.14 (17.45–22.33) | 22.01 (19.27–27.16) | 0.028** |
| Body surface area (m2) median (range) | 1.48 (1.41–1.72) | 1.67 (1.40–1.98) | 0.072** |
| Daily IM dose (mg) median (range) | 400 (200–400) | 400 (200–400) | 0.594** |
| IM duration (months) median (range) | 86 (56–126) | 96 (51–138) | 0.744** |
| IM-DMR (months) median (range) | 28 (19–44) | 38 (11–84) | 0.340** |
| DMR-IM cessation (months) median (range) | 56 (36–97) | 50 (31–93) | 0.890** |
| MR3.0 maintence after IM cessation | yes 7 no 0 | yes 12 no 5 | 0.077*** |
Abbreviations: IFNα, interferonα; IM, imatinib; DMR, deep molecular response. Statistical analysis was performed with Graph PAD Prism 6 (GraphPad Software, San Diego, CA).
*
with Fisher's exact test.
**
Mann-Whitney U test.
***
Log-rank test.